© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
Peter Staley speaks with Dr. Donald Kotler, chief of gastroenterology at St. Luke’s Roosevelt Hospital in New York and a longtime researcher
Your CROI cheatsheet—featuring drug news, HIV’s family tree, the skinny on blood fats and more from the biggest HIV science conference.
Dr. Calvin Cohen discusses Kaletra vs. Sustiva, the newly infected showing HIV drug resistance, and HIVers dying from non-AIDS cancers
Thoughts on the sophisticated genetic research that is providing experts with tools they need to unwrap the mystery of the origins of HIV.Â...
An analysis of two Gilead-sponsored studies suggests that black HIV-positive patients have a better chances of an undetectable viral load afte...
Dr. Cal Cohen discusses the new integrase & CCR5 inhibitors, and a new non-nuke
Dr. Don Kotler discusses news from CROI about lipodystrophy, bone loss, and metabolic problems
An ACTG study indicates that once-daily and twice-daily Kaletra are comparable in patients over 48 weeks of treatment, but also suggests that...
New research concludes that hepatitis B virus (HBV) treatment Baraclude (entecavir) is active against HIV, suggesting that that the drug will...
While HIV meds play a role in rates of cholesterol in HIV-positive people, it also appears diets rich in fat are likely culprits as well. Â
MD turns his gaze to the recent spate of data promoting the use of anti-herpes drugs to reduce HIV transmission and disease progression.
Tibotec’s experimental NNRTI performs well in a clinical trial pitting it against standard-of-care Sustiva in treatment-naive patients.Â
Researchers have reported HIV-positive patients are less likely to benefit from lipid-lowering therapy than their HIV-negative counterparts.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.